For the newly established Cluster for Nucleic Acid Therapeutics Munich (C-NATM),
the Institute of Pharmacology and Toxicology at Technical University of Munich (TUM) is seeking a
Postdoctoral scientist (m/w/d) for RNA – therapeutics
starting at the earliest possible date.
Nucleic acid therapeutics are about to become a third pillar of medicine, next to synthetic small molecules and biologicals. To propel the development of nucleic-acid-based therapeutics and their translation to the clinic, we at TUM and our partner LMU founded the Cluster for Nucleic Acids Therapeutics Munich (CNATM) as part of the BMBF clusters4future program. CNATM started in 2023 and comprises 19 academic research groups and 16 industrial partners. It is our dedicated goal to develop nucleic-acid-based drugs for thus far insufficiently treatable diseases.
About the institute
The Institute of Pharmacology and Toxicology (IPT) is part of the Medical Faculty at the Technical University of Munich (TUM), one of the leading universities worldwide and ranked 1st in Germany. Next to CNATM, we take the lead in the DFG-funded collaborative research center TRR267 “Non-coding RNA in the cardiovascular system”. The IPT is at the forefront of research on non-coding RNAs and the effects of their therapeutic manipulation in disease. We established the role of macrophage RNomes in cardiac and pulmonary disease (Science, 2023; Circulation, 2021) and developed ligand-coupled oligonucleotides for therapy (Nature Commun, 2023).
We are seeking:
- To support the development of nucleic-acid-based drugs, we seek for early-career scientists (postdoctoral level) with excellent contributions to the field of nucleic acid research and therapy. A track record of ≥1 research articles (first or last authorship) in a renown peer-reviewed journal is required.
- Applicants with strong educational background in RNA biology, chemistry/biochemistry and/or omics technologies (ideally with computational background in a Linux/Unix and R programming).
- Candidates from related relevant fields, e.g. chemical synthesis of nucleic acids or CRISPR engineering, are also welcome to apply.
- A highly productive research network of academic and industrial partners in one of the fastest developing and most fascinating fields of medicine.
- An inspiring international work environment with strong on-topic expertise and scientific output of highest quality.
- Established state-of-the-art research infrastructure and methodology, e.g. disease phenotyping, human iPS cell programming, light sheet microscopy and the entire experimental pipeline for next-generation sequencing from tissue or single-cells, including FACS-based cell separation
- Excellent opportunities and support programs for your transition to group leadership and tenure track.
The position is initially limited to 3 years, with the option of prolongation. Salary will be according to level TVL-13.
The TUM aims to substantially increase diversity of its staff. As equal opportunity and affirmative action employer, the TUM explicitly encourages applications from women as well as from all others who would bring additional diversitydimensions to the university’s research and teaching strategies. Preference will be given to disabled candidates with essentially the same qualifications.
Please send your application (one pdf file, including cover letter,C.V., recommendations/references, certificates) via email to: email@example.com, subject: “AP_WP6/7_2023”. Applications will be considered as they are received and until positions are filled.
Institut für Pharmakologie und Toxikologie
Technische Universität München
TUM Office at CNATM
Prof. Dr. Dr. Stefan Engelhardt
Biedersteiner Straße 29
Tel. +49 89 4140 3260
Data privacydeclaration: By your recruitment application, you are submitting personalized data to the Technische Universität München (TUM). Please note our Data protection information for processing personal data in relationto your application.Upon submission of your application, you confirm to have taken notice of this data protection policy.